EDAP Announces 23% First Quarter 2013 Revenue Growth

EDAP Announces 23% First Quarter 2013 Revenue Growth

  *First quarter total revenue of approximately EUR 5.9 million (USD 7.8
    million), up 23% year-over-year
  *Ten lithotripsy devices sold in first quarter 2013
  *Received FDA acceptance for PMA filing on March 26, 2013, for
    Ablatherm®-HIFU for treatment of low risk, localized prostate cancer

LYON, France, April 11, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP),
the global leader in therapeutic ultrasound, announced today preliminary
unaudited revenues for the first quarter ended March 31, 2013.

Preliminary total revenue for the first quarter 2013 is expected to be
approximately EUR 5.9 million (USD 7.8 million), a 23% year-over-year
increase. First quarter 2013 total revenue reflected the sales of ten
lithotripters and one Ablatherm-HIFU device.

Marc Oczachowski, EDAP's Chief Executive Officer, commented, "Our first
quarter 2013 revenue reflects the ongoing global demand for our innovative
range of lithotripsy offerings.We are poised for continued growth as we
expand our sales operations and increase our market penetration."

EDAP plans to hold a conference call to discuss its first quarter 2013
financial results on Thursday, May 16, 2013, at 8:30 am EDT.


EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound
(HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a
minimally invasive and effective treatment option with a low occurrence of
side effects. Ablatherm-HIFU is generally recommended for patients with
localized prostate cancer (stages T1-T2) who are not candidates for surgery or
who prefer an alternative option, or for patients who failed radiotherapy
treatment., Ablatherm-HIFU is approved and commercialized in Europe as a
treatment for prostate cancer and is currently under regulatory review in the
U.S. following submission of the Pre-Market Approval Application in February
2013 after the completion ofa multi-center U.S. Phase II/III clinical trial
under an Investigational Device Exemption (IDE) granted by the FDA. The
Company also develops its HIFU technology for the potential treatment of
certain other types of tumors. EDAP TMS SA also produces and commercializes
medical equipment (the Sonolith® range) for treatment of urinary tract stones
using extra-corporeal shockwave lithotripsy (ESWL). For more information on
the Company, please visit http://www.edap-tms.com, and

Forward-Looking Statements

In addition to historical information, this press release may contain
forward-looking statements that involve risks and uncertainties. Such
statements are based on management's current expectations and are subject to a
number of uncertainties, including the uncertainties of the regulatory
process, and risks that could cause actual results to differ materially from
those described in these forward-looking statements. Factors that may cause
such a difference include, but are not limited to, those described in the
Company's filings with the Securities and Exchange Commission and in
particular, in the sections "Cautionary Statement on Forward-Looking
Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.
Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or
marketed in the United States.

CONTACTS:  Blandine Confort
           Investor Relations / Legal Affairs
           EDAP TMS SA +33 4 72 15 31 72

           Stephanie Carrington  The Ruth Group
Press spacebar to pause and continue. Press esc to stop.